In 2025, medically integrated dispensing pharmacies face significant challenges, including low reimbursements, restrictive pharmacy benefit manager practices, complex therapies, regulatory barriers such as the Stark delivery law, and the Inflation Reduction Act's financial implications, necessitating urgent advocacy, reform, and collaboration to sustain equitable, patient-centered cancer care.
Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.
With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Offering individual advice and counseling to patients can help combat the risks of driving under the influence of prescription drugs.
AI-enabled remote cardiac telemetry can help manage stress’s effects on high-risk populations.
Although COVID-19 paused our original plans, we were ultimately able to reach more people than we ever could have via in-person presentations alone.
Measures like hassle-free safe sharps disposal packaging save critical staff time and resources.
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
Providers who are sensitive to health literacy have contributed to positive quality improvement across various institutions.
PBM reforms and regulatory changes have reshaped the industry landscape.
The SHARE model from the CDC involves personalizing recommendations for patients and their needs, addressing any concerns they may have, and explaining the risks of remaining unvaccinated.
Both benefits and concerns exist, but implementing policies and regulations promotes employee productivity, guards safety.
Educational programming for pharmacy students and practicing pharmacists on medication abortion is limited.
When it comes to vaccination efforts, remember that patients 65 years or older are not a homogeneous group.
As evidence for omega-3 continues to develop, pharmacists remain poised to guide patients toward the most indicated, safe, effective, and convenient options available.
Pharmacists are pivotal in expanding reproductive health care access through patient education and collaboration.
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.
Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.
Successful integration demands overcoming various hurdles.
The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.
Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.
Because patients may interact with a pharmacist more regularly than other health care providers, it is possible to detect potential signs and symptoms of atrial fibrillation in a patient during their encounters.
As data continue to develop in this arena, β-lactam therapeutic drug monitoring is likely to become more routine, as it has with drugs like vancomycin and the aminoglycosides.
Atopic dermatitis significantly impacts quality of life, and requires personalized management through trigger identification, skin barrier maintenance, and a range of topical, oral, and biologic therapies to reduce symptoms and prevent flare-ups.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Collaborating with patient advocacy organizations offers pharmacy students a unique opportunity to make a meaningful impact in health care.
Their exclusion ripples into demand estimates for pharmacists, leading to a distorted picture of pharmacist demand and, ultimately, impacting the number of individuals choosing to enter the profession.
The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.
The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.